Avantor can show near-term resilience before outperforming in the long term, according to RBC Capital Markets. Analyst Conor McNamara initiated coverage of the health care products stock at outperform. His $27 price target implies a 37.4% upside from where shares finished Tuesday. AVTR YTD mountain Avantor Avantor is well-positioned for the long-term, McNamara said, as the life science tools sector is one of the most attractive in health care. Though the price target would require the stock to trade at historical multiples relative to peers, McNamara said that would be justified after the company's operating improvements in recent years.

---

Persons: Conor McNamara, McNamara, — CNBC's Michael Bloom Organizations: RBC Capital Markets